Document:

Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

CONSTELLATION ALPHA CAPITAL CORP.

Emerald View, Suite 400

2054 Vista Parkway

West Palm Beach, FL 33411

 

Ladies and Gentlemen:

 

In connection
with the proposed business combination (the “Transaction”) in which DermTech, Inc., a Delaware Corporation (“DermTech”)
will merge with a wholly-owned subsidiary corporation of Constellation Alpha Capital Corp., a company incorporated in the British
Virgin Islands and which is expected to re-domicile in the State of Delaware (the “Company”), the undersigned
desires to subscribe for and purchase from the Company, and the Company desires to sell to the undersigned, that number of shares
of common stock (the “Company Shares”) of the Company set forth on the signature page hereof for a purchase
price of $3.25 per share, on the terms and subject to the conditions contained herein. In connection therewith, the undersigned
and the Company agree as follows:

 

1.          Subscription.
The undersigned hereby irrevocably subscribes for and agrees to purchase from the Company such number of Company Shares as is set
forth on the signature page of this Subscription Agreement on the terms and subject to the conditions provided for herein (the
 “Shares”). The undersigned understands and agrees that the Company reserves the right to accept or reject the
undersigned’s subscription for the Shares for any reason or for no reason, in whole or in part, at any time prior to its
acceptance by the Company, and the same shall be deemed to be accepted by the Company only when this Subscription Agreement is
signed by a duly authorized person by or on behalf of the Company; the Company may do so in counterpart form. In the event of rejection
of the subscription (in whole or in part) by the Company or the termination of this subscription in accordance with the terms hereof,
the undersigned’s payment hereunder will be returned promptly (within three (3) days) to the undersigned along with this
Subscription Agreement, and this Subscription Agreement shall have no force or effect. The Company expects to enter into substantially
this same form of subscription agreement with certain other investors (the “Other Purchasers”) and expects to
complete the sale of Company Shares to them.

 

2.          Closing.
The closing of the sale of the Shares contemplated hereby (the “Closing”) is contingent upon the substantially
concurrent consummation of the Transaction. The Closing shall occur on the date of, and immediately prior to, the consummation
of the Transaction. Following written notice from (or on behalf of) the Company to the undersigned (the “Closing Notice”)
that the Company reasonably expects (i) all conditions to the closing of the Transaction to be satisfied or waived and (ii) the
Closing to occur on a date that is not less than ten (10) business days from the date of the Closing Notice, the undersigned shall
deliver to the Company, no sooner than three (3) business days prior to the anticipated Closing date specified in the Closing Notice
(the “Closing Date”), the subscription amount for the Shares by wire transfer of United States dollars in immediately
available funds to the account specified by the Company in the Closing Notice against delivery to the undersigned of the Shares
in book entry form as set forth in the following sentence. The Company shall deliver (or cause the delivery of) the Shares in book
entry form to the undersigned or to a custodian designated by undersigned, as applicable, as indicated below. This Subscription
Agreement shall terminate and be of no further force or effect, without any liability to either party hereto, if the Company notifies
the undersigned in writing that it has abandoned its plans to move forward with the Transaction. If this Subscription Agreement
terminates following the delivery by the undersigned of the purchase price for the Shares, the Company shall promptly return the
purchase price to the undersigned.

 

    	 	1	 

     

    

 

3.          Closing
Conditions. The Closing is also subject to the conditions that, on the Closing Date:

 

a.           all
representations and warranties of the Company and the undersigned contained in this Subscription Agreement shall be true and correct
in all material respects (other than representations and warranties that are qualified as to materiality or Material Adverse Effect
(as defined herein), which representations and warranties shall be true in all respects) at and as of the Closing Date, and consummation
of the Closing shall constitute a reaffirmation by each of the Company and the undersigned of each of the representations, warranties
and agreements of each such party contained in this Subscription Agreement as of the Closing Date, but in each case without giving
effect to consummation of the Transaction;

 

b.           no
governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order, law, rule or regulation
(whether temporary, preliminary or permanent) which is then in effect and has the effect of making consummation of the transactions
contemplated hereby illegal or otherwise restraining or prohibiting consummation of the transactions contemplated hereby, and no
governmental authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint or prohibition;

 

c.           the
Company is a company incorporated under the laws of the State of Delaware and will be treated as a U.S. corporation for U.S. federal
income tax purposes;

 

d.           there
have been no material changes to the material terms of the Transaction set forth on Schedule D;

 

e.           all
conditions precedent to the closing of the Transaction, including the approval of the Company’s stockholders, shall have
been satisfied or waived (other than those conditions which, by their nature, are to be satisfied at the closing of the Transaction);
and

 

f.            no
suspension of the qualification of the Shares for offering or sale or trading in any jurisdiction, or initiation or threatening
of any proceedings for any of such purposes, shall have occurred.

 

4.          Further
Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional
actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated
by this Subscription Agreement.

 

    	 	2	 

     

    

 

5.          Company
Representations and Warranties. The Company represents and warrants to the undersigned that, as of the date hereof and as of
the Closing:

 

a.           The
Company has been duly organized, is validly existing and is in good standing under the laws of the jurisdiction of its formation
or incorporation, with corporate power and authority to own, lease and operate its properties and conduct its business as presently
conducted.

 

b.           The
Shares have been duly authorized and, when issued and delivered to the undersigned against full payment therefor in accordance
with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have
been issued in violation of or subject to any preemptive or similar rights created under the Company’s governance documents
or under the laws of the jurisdiction under which it has been organized.

 

c.           The
execution, delivery and performance by the Company of this Subscription Agreement are within its powers, have been duly authorized
and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court or
other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the Company is a party
or by which the Company is bound, and will not violate any provisions of the Company’s charter documents, including, without
limitation, its incorporation or formation papers and bylaws. The signature on this Subscription Agreement by the Company is genuine,
and the signatory has been duly authorized to execute the same, and this Subscription Agreement constitutes a legal, valid and
binding obligation of the Company, enforceable against it in accordance with its terms, except as may be limited or otherwise affected
by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights
of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

d.           The
issuance and sale of the Shares and the compliance by the Company with all of the provisions of this Subscription Agreement and
the consummation of the transactions herein will not conflict with or result in a breach or violation of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property
or assets of the Company or any of its subsidiaries pursuant to the terms of (i) any indenture, mortgage, deed of trust, loan agreement,
lease, license or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any of the property or assets of the Company is subject, which would have a material
adverse effect on the business, properties, financial condition, stockholders’ equity or results of operations of the Company
(a “Material Adverse Effect”) or affect the validity of the Shares or the legal authority of the Company to
comply in all material respects with the terms of this Subscription Agreement; (ii) result in any violation of the provisions of
the organizational documents of the Company; or (iii) result in any violation of any statute or any judgment, order, rule or regulation
of any court or governmental agency or body, domestic or foreign, having jurisdiction over the Company or any of its properties
that would have a Material Adverse Effect or affect the validity of the Shares or the legal authority of the Company to comply
with this Subscription Agreement.

 

    	 	3	 

     

    

 

e.           The
Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and has filed all reports required thereby. To the Company’s knowledge, there exist no facts or circumstances that reasonably
could be expected to prohibit or delay the preparation and filing of a Securities Act registration statement on Form S-3 that will
be available for the resale of the Shares by the undersigned as contemplated by Section 7 below.

 

f.            As of the date of this Subscription Agreement, the authorized shares of capital stock of the Company consists of an unlimited number
of shares of common stock and an unlimited number of shares of preferred stock. As of the date of this Subscription Agreement,
(i) 4,155,000 shares of Company common stock are issued and outstanding (which excludes 1,187,532 shares subject to redemption
rights provided in the amended and restated articles of association of the Company), all of which are validly issued, fully paid
and non-assessable, (ii) no shares of Company common stock are held in treasury, (iii) the Company has reserved for future issuance
7,468,125 shares of Company common stock pursuant to outstanding warrants, and (iv) the Company has reserved for future issuance
1,493,625 shares of Company common stock pursuant to outstanding rights. As of the date of this Subscription Agreement, there are
no shares of Company preferred stock issued and outstanding. Except for the warrants and rights mentioned above, there are no options,
warrants or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued capital stock
of the Company or obligating the Company to issue or sell any shares of capital stock of, or other equity interests in, the Company.
There are no outstanding contractual obligations of the Company to repurchase, redeem or otherwise acquire any shares of Company
common stock, except for the redemption rights described above. There are no outstanding contractual obligations of the Company
to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, any person. The Company
has issued promissory notes in the amounts and to the parties set forth in Schedule E.

 

g.           There
are no suits, proceedings or legal or governmental actions pending, or to the Company’s knowledge, threatened, before any
court, regulatory body or administrative agency, or any other governmental agency or body, which suits, proceedings or actions,
individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. The Company is not a party to
or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body administrative agency or
other governmental agency or body that could reasonably be expected to have a Material Adverse Effect.

 

    	 	4	 

     

    

 

h.           Since
December 31, 2018, (i) there has not been any change in the capital stock of the Company (other than the sale of the Shares hereunder,
the sale of additional Company Shares to the Other Purchasers, Company Shares redeemed in connection with the Company’s special
meeting of shareholders held on March 21, 2019 to approve an extension to the amount of time it has to complete a business combination
and the issuance of Company Shares pursuant to the Transaction, in each case as of the Closing), and (ii) there has not occurred
any event that has caused or reasonably could be expected to cause a Material Adverse Event.

 

i.            None
of the following documents contained or contains a an untrue statement of a material fact or omitted or omits to state a material
fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were
made, not misleading: (i) the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2018; (ii) the Company’s
Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2018, September 30, 2018 and December 31, 2018; (iii) the
Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on
August 3, 2018, December 4, 2018, February 28, 2019, March 15, 2019 and March 25, 2019; (iv) all other documents filed by the Company
with the SEC since the filing of the above-mentioned Form 10-K; and (v) the Disclosure Package (as defined below). In the past
12 calendar months, the Company has filed all documents required to be filed by it prior to the date hereof with the SEC pursuant
to the reporting requirements of the Exchange Act.

 

j.            The
financial statements of the Company and the related notes and schedules thereto included in the Company’s Exchange Act filings
fairly present in all material respects the financial position, results of operations, stockholders’ equity and cash flows
of the Company as of the dates and for the periods specified therein. Such financial statements and the related notes and schedules
thereto have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods
involved and all adjustments necessary for a fair presentation of results for such periods have been made; provided, however,
that the Company’s unaudited financial statements are subject to normal year-end adjustments.

 

k.           Except
as described in the Company’s Current Report on Form 8-K filed with the SEC on February 28, 2019, the Company is in compliance
with the requirements of the NASDAQ Capital Market (“Nasdaq”) for continued listing thereon of the Company Shares.
The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Company Shares
under the Exchange Act or the listing of the Company Shares on Nasdaq, nor, except as disclosed in the Company’s Current
Report on Form 8-K filed with the SEC on February 28, 2019, has the Company received any notification that the SEC or Nasdaq is
contemplating terminating such registration or listing. The transactions contemplated by this Subscription Agreement will not contravene
the rules and regulations of Nasdaq. The Company will comply with all requirements of Nasdaq with respect to the issuance of the
Shares hereunder and the issuance of Company Shares to the Other Purchasers, and shall cause the Shares to be approved for listing
on Nasdaq (and any other exchange on which the Company Shares are listed for trading) not later than the Closing.

 

    	 	5	 

     

    

 

6.          Subscriber
Representations and Warranties. The undersigned represents and
warrants to the Company that, as of the date hereof and as of the Closing:

 

a.           The
undersigned is (i) a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act of 1933, as
amended (the “Securities Act”)) or (ii) an institutional “accredited investor” (within the meaning
of Rule 501(a) under the Securities Act), in each case, satisfying the requirements set forth on Schedule A, and is acquiring
the Shares only for his, her or its own account and not for the account of others, and not on behalf of any other account or person
or with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and shall
provide the requested information on Schedule A following the signature page hereto). The undersigned is not an entity formed
for the specific purpose of acquiring the Shares.

 

b.           The
undersigned understands that the Shares are being offered in a transaction not involving any public offering within the meaning
of the Securities Act and that the Shares have not been registered under the Securities Act. The undersigned understands that the
Shares may not be resold, transferred, pledged or otherwise disposed of by the undersigned absent an effective registration statement
under the Securities Act except (i) to the Company or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales
that occur outside the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable
exemption from the registration requirements of the Securities Act, and in each of cases (i) and (iii) in accordance with any applicable
securities laws of the states and other jurisdictions of the United States, and that any certificates representing the Shares shall
contain a legend to such effect. The undersigned acknowledges that the Shares will not be eligible for resale pursuant to Rule
144A promulgated under the Securities Act. The undersigned understands and agrees that the Shares will be subject to transfer restrictions
and, as a result of these transfer restrictions, the undersigned may not be able to readily resell the Shares and may be required
to bear the financial risk of an investment in the Shares for an indefinite period of time. The undersigned understands that it
has been advised to consult legal counsel prior to making any offer, resale, pledge or transfer of any of the Shares.

 

c.           The
undersigned understands and agrees that the undersigned is purchasing Shares directly from the Company. The undersigned further
acknowledges that there have been no representations, warranties, covenants and agreements made to the undersigned by the Company,
or its officers or directors, expressly or by implication, other than those representations, warranties, covenants and agreements
included in this Subscription Agreement.

 

d.           The
undersigned’s acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited transaction
under Section 406 of the Employee Retirement Income Security Act of 1974, as amended, Section 4975 of the Internal Revenue Code
of 1986, as amended, or any applicable similar law.

 

    	 	6	 

     

    

 

e.           The
undersigned acknowledges and agrees that the undersigned has received such information as the undersigned deems necessary in order
to make an investment decision with respect to the Shares. Without limiting the generality of the foregoing, the undersigned acknowledges
that it has reviewed the disclosure package attached hereto as Schedule C (the “Disclosure Package”).
The undersigned represents and agrees that the undersigned and the undersigned’s professional advisor(s), if any, have had
the full opportunity to ask such questions, receive such answers and obtain such information as the undersigned and such undersigned’s
professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares. The undersigned
further acknowledges that the information contained in the Disclosure Package is preliminary and subject to change, and that any
changes to the information contained in the Disclosure Package, including, without limitation, any changes based on updated information
or changes in terms of the Transaction (other than the material terms set forth on Schedule D which shall not have materially
changed), shall in no way affect the undersigned’s obligation to purchase the Shares hereunder.

 

f.            The
undersigned became aware of this offering of the Shares solely by means of direct contact between the undersigned and the Company
or a representative of the Company, and the Shares were offered to the undersigned solely by direct contact between the undersigned
and the Company or a representative of the Company. The undersigned did not become aware of this offering of the Shares, nor were
the Shares offered to the undersigned, by any other means. The undersigned acknowledges that the Company represents and warrants
that the Shares (i) were not offered by any form of general solicitation or general advertising and (ii) are not being offered
in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities
laws.

 

g.           The
undersigned acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares,
including those set forth in the Disclosure Package. The undersigned has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the undersigned has sought such
accounting, legal and tax advice as the undersigned has considered necessary to make an informed investment decision.

 

h.           Alone,
or together with any professional advisor(s), the undersigned has adequately analyzed and fully considered the risks of an investment
in the Shares and determined that the Shares are a suitable investment for the undersigned and that the undersigned is able at
this time and in the foreseeable future to bear the economic risk of a total loss of the undersigned’s investment in the
Company. The undersigned acknowledges specifically that a possibility of total loss exists.

 

i.            In
making its decision to purchase the Shares, the undersigned has relied solely upon independent investigation made by the undersigned.
Without limiting the generality of the foregoing, the undersigned has not relied on any statements or other information provided
by the Placement Agent (as defined below) concerning the Company or the Shares or the offer and sale of the Shares.

 

    	 	7	 

     

    

 

j.            The
undersigned understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the
Shares or made any findings or determination as to the fairness of this investment.

 

k.           The
undersigned has been duly formed or incorporated and is validly existing in good standing under the laws of its jurisdiction of
incorporation or formation.

 

l.            The
execution, delivery and performance by the undersigned of this Subscription Agreement are within the powers of the undersigned,
have been duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or
regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to
which the undersigned is a party or by which the undersigned is bound, and, if the undersigned is not an individual, will not violate
any provisions of the undersigned’s charter documents, including, without limitation, its incorporation or formation papers,
bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement
is genuine, and the signatory, if the undersigned is an individual, has legal competence and capacity to execute the same or, if
the undersigned is not an individual the signatory has been duly authorized to execute the same, and this Subscription Agreement
constitutes a legal, valid and binding obligation of the undersigned, enforceable against the undersigned in accordance with its
terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium
or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at
law or equity.

 

m.          Neither
the due diligence investigation conducted by the undersigned in connection with making its decision to acquire the Shares nor any
representations and warranties made by the undersigned herein shall modify, amend or affect the undersigned’s right to rely
on the truth, accuracy and completeness of the Company’s representations and warranties contained herein.

 

n.           The
undersigned is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered
by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive Order
issued by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity prohibited
by any OFAC sanctions program, (ii) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515,
or (iii) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank (collectively, a “Prohibited
Investor”). The undersigned agrees to provide law enforcement agencies, if requested thereby, such records as required
by applicable law, provided that the undersigned is permitted to do so under applicable law. If the undersigned is a financial
institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.) (the “BSA”), as amended by the
USA PATRIOT Act of 2001 (the “PATRIOT Act”), and its implementing regulations (collectively, the “BSA/PATRIOT
Act”), the undersigned maintains policies and procedures reasonably designed to comply with applicable obligations under
the BSA/PATRIOT Act. To the extent required, it maintains policies and procedures reasonably designed for the screening of its
investors against the OFAC sanctions programs, including the OFAC List. To the extent required, it maintains policies and procedures
reasonably designed to ensure that the funds held by the undersigned and used to purchase the Shares were legally derived.

 

    	 	8	 

     

    

 

o.           No
disclosure or offering document has been prepared by Cowen and Company, LLC (the “Placement Agent”) or any of
its affiliates in connection with the offer and sale of the Shares.

 

p.           The
Placement Agent and its directors, officers, employees, representatives and controlling persons have made no independent investigation
with respect to the Company or the Shares or the accuracy, completeness or adequacy of any information supplied to the undersigned
by the Company.

 

q.           In
connection with the issue and purchase of the Shares, the Placement Agent has not acted as the undersigned’s financial advisor
or fiduciary.

 

r.            If
the undersigned is a resident or subject to the laws of Canada, the undersigned hereby declares, represents, warrants and agrees
as set forth in the attached Schedule B.

 

7.          Registration
of Shares. The Company agrees that, within forty-five (45) calendar days after the consummation of the Transaction, the Company
will file with the SEC (at the Company’s sole cost and expense) a registration statement registering such resale (the “Registration
Statement”), and the Company shall use its commercially reasonable efforts to have the Registration Statement declared
effective as soon as practicable after the filing thereof; provided, however, that the Company’s obligations
to include the Shares in the Registration Statement are contingent upon the undersigned furnishing in writing to the Company such
information regarding the undersigned, the securities of the Company held by the undersigned and the intended method of disposition
of the Shares as shall be reasonably requested by the Company to effect the registration of the Shares, and shall execute such
documents in connection with such registration as the Company may reasonably request that are customary of a selling stockholder
in similar situations.

 

8.          [Reserved]

 

9.          Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the
parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to
occur of (a) following the execution of a definitive agreement among the Company and DermTech with respect to the Transaction (a
 “Transaction Agreement”), such date and time as such Transaction Agreement is terminated in accordance with
its terms without the Transaction being consummated, (b) upon the mutual written agreement of each of the parties hereto to terminate
this Subscription Agreement, (c) if any of the conditions to Closing set forth in Section 3 of this Subscription Agreement are
not satisfied or waived on or prior to the Closing and, as a result thereof, the transactions contemplated by this Subscription
Agreement are not consummated at the Closing or (d) September 24, 2019; provided that nothing herein will relieve any party
from liability for any willful breach hereof prior to the time of termination, and each party will be entitled to any remedies
at law or in equity to recover losses, liabilities or damages arising from such breach. The Company shall promptly notify the undersigned
of the termination of the Transaction Agreement after the termination of such agreement.

 

    	 	9	 

     

    

 

10.        Trust
Account Waiver. The undersigned acknowledges that the Company is a blank check company with the powers and privileges to effect
a merger, asset acquisition, reorganization or similar business combination involving the Company and one or more businesses or
assets. The undersigned further acknowledges that, as described in the Company’s prospectus relating to its initial public
offering dated June 19, 2017 (the “Prospectus”) available at www.sec.gov, substantially all of the Company’s
assets consist of the cash proceeds of the Company’s initial public offering and private placements of its securities, and
substantially all of those proceeds have been deposited in a trust account (the “Trust Account”) for the benefit
of the Company, its public shareholders and the underwriters of the Company’s initial public offering. For and in consideration
of the Company entering into this Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged, the undersigned
hereby irrevocably waives any and all right, title and interest, or any claim of any kind it has or may have in the future, in
or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account as a result of, or arising
out of, this Subscription Agreement.

 

11.        Placement
Agent Fee. The Company and the undersigned agree that the undersigned shall not be responsible or otherwise have any liability
for the payment of any fee to the Placement Agent. The Company represents and warrants to the undersigned that the Company has
not engaged or employed any finder, broker, agent or other intermediary, other than the Placement Agent, in connection with the
transactions described herein. There are no fees, commissions or compensation payable by the undersigned to any person engaged
or retained by, through or on behalf of the Company in connection with the consummation of the transactions described herein.

 

12.        Miscellaneous.

 

a.           Neither
this Subscription Agreement nor any rights or obligations that may accrue hereunder (other than the Shares acquired hereunder,
if any) may be transferred or assigned by the Company or the undersigned without the consent of the other party.

 

b.           The
Company may request from the undersigned such additional information as the Company may deem necessary to evaluate the eligibility
of the undersigned to acquire the Shares, and the undersigned shall provide such information as may reasonably be requested, to
the extent readily available and to the extent consistent with its internal policies and procedures.

 

    	 	10	 

     

    

 

c.           The
undersigned acknowledges that the Company, the Placement Agent and others will rely on the acknowledgments, understandings, agreements,
representations and warranties contained in this Subscription Agreement. Prior to the Closing, the undersigned agrees to promptly
notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth herein are
no longer accurate. The undersigned agrees that each purchase by the undersigned of Shares from the Company will constitute a reaffirmation
of the acknowledgments, understandings, agreements, representations and warranties herein (as modified by any such notice) by the
undersigned as of the time of such purchase. The undersigned further acknowledges and agrees that the Placement Agent is a third-party
beneficiary of the representations and warranties of the undersigned contained in Section 6 of this Subscription Agreement.

 

d.           The
Company is entitled to rely upon this Subscription Agreement and is irrevocably authorized to produce this Subscription Agreement
or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters
covered hereby.

 

e.           All
the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive the Closing.

 

f.            This
Subscription Agreement may not be modified, waived or terminated except by an instrument in writing, signed by the party against
whom enforcement of such modification, waiver, or termination is sought.

 

g.           This
Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations
and warranties, both written and oral, among the parties, with respect to the subject matter hereof. Except as otherwise expressly
set forth in subsection (c) of this Section 11, this Subscription Agreement shall not confer any rights or remedies upon any person
other than the parties hereto, and their respective successor and assigns.

 

h.           Except
as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto
and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations,
warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns.

 

i.            If
any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality or enforceability
of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby and shall continue in full force
and effect.

 

j.            This
Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by
different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts
so executed and delivered shall be construed together and shall constitute one and the same agreement.

 

    	 	11	 

     

    

 

k.           The
parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Subscription Agreement
were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement and to enforce specifically
the terms and provisions of this Subscription Agreement, this being in addition to any other remedy to which such party is entitled
at law, in equity, in contract, in tort or otherwise.

 

l.            The
obligations of the undersigned under this Subscription Agreement are several and not joint with the obligations of any Other Purchaser
under any other subscription agreement. The undersigned shall be entitled independently to protect and enforce its rights, including
its rights arising under this Subscription Agreement, and it shall not be necessary for any Other Purchaser to be joined as an
additional party in any proceeding for such purpose. Nothing contained in this Subscription Agreement or any subscription agreement
entered into by any Other Purchaser, and no action taken by the undersigned pursuant hereto or any Other Purchaser pursuant thereto,
shall be deemed to constitute the undersigned and any Other Purchaser(s) as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the undersigned and any Other Purchaser(s) are acting as a group with respect
to the transactions contemplated hereby or thereby.

 

m.          THIS
SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE. EACH PARTY HERETO
HEREBY WAIVES ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS SUBSCRIPTION AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED HEREBY.

 

[SIGNATURE PAGES FOLLOW]

 

    	 	12	 

     

    

 

IN WITNESS WHEREOF, the
undersigned has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the date
set forth below.

 

	Name of Investor:	 	State/Country of Formation or Domicile:
	 	 	 
	By:	 	 	 
	 	 	 	 
	Name:	 	 	 
	 	 	 	 
	Title: 	 	 	 

 

	Name in which shares are to be registered (if different):	 	Date: ______________, 2019
	 	 	 
	Investor’s EIN:	 	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	City, State, Zip:	 	City, State, Zip:
	 	 	 
	Attn:________________	 	Attn:________________
	 	 	 
	Telephone No.:	 	Telephone No.:
	 	 	 
	Facsimile No.:	 	Facsimile No.:
	 	 	 
	Number of Shares:	 	[   ] (subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market)
	 	 	 
	Aggregate Subscription Amount: $	 	Price Per Share: $3.25 (subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market)

 

You must
pay the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account specified by
the Company in the Closing Notice. To the extent the offering is oversubscribed, the number of Shares received may be less than
the number of Shares subscribed for, in which case the excess payment representing the undersigned’s unfulfilled number of
Shares shall be promptly returned to the undersigned in accordance with Section 1 of this Agreement.

 

 

    	 	13	 

     

    

 

IN WITNESS WHEREOF, the
Company has accepted this Subscription Agreement as of the date set forth below.

 

	 	CONSTELLATION ALPHA CAPITAL CORP.
	 	 	 
	 	By:	                 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	Date:________________, 2019	 	 

 

    	 	14Exhibit 10.2

 

DEFERRED UNDERWRITING FEE ASSIGNMENT
AGREEMENT

 

Cowen and Company, LLC

As Representative of the several Underwriters

c/o Cowen and Company, LLC

1221 Avenue of the Americas

New York, New York 10020

 

May 29, 2019

		Re:	Deferred
Underwriting Fee Assignment Agreement

 

Ladies and Gentlemen:

 

This deferred underwriting
fee assignment agreement (this “Fee Agreement”) is being delivered to you in connection with that certain
Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among Cowen
and Company, LLC (“Cowen”), acting as representative of the underwriters named in Schedule A thereto
(the “Underwriters”), and Constellation Alpha Capital Corp., a company incorporated in the British Virgin
Islands (“Constellation”), and the proposed business combination by and among DermTech, Inc., a Delaware
corporation (the “Company”), Constellation and a wholly-owned subsidiary of Constellation, whereby the
Company would survive the business combination as a wholly-owned subsidiary of Constellation, and the existing stockholders of
the Company would own a majority of the voting securities of Constellation following the business combination (the “Merger”).
For the avoidance of doubt, the Merger shall not include any business combination which results in the existing stockholders of
the Company owning less than a majority of the voting securities of Constellation following such business combination.

 

Pursuant to the terms
of the Underwriting Agreement, Constellation has agreed to pay to the Underwriters the Deferred Discount (as defined therein),
which is equal to $4,375,000 (the “Original Fee”).

 

For good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Constellation agrees to assign to the Company, and
the Company agrees to assume, Constellation’s obligation pursuant to the Underwriting Agreement to pay to the Underwriters
the Original Fee (the “Assignment”), pursuant to the following terms and conditions:

 

		1.	The Assignment set forth herein (including with respect
to the payment obligations and terms set forth in Sections 2-4 below) shall be effective only if and when the Merger consummates,
provided that the Assignment shall not be effective in the event of any Merger consummated after September 23, 2019.

 

		2.	If the Merger has consummated and Constellation has raised
at least an additional $15,000,000 (the “Post-Closing Proceeds”) pursuant to proceeds received from
one or more equity financings consummated after the closing of the Merger (the “Closing”) and by the
twelve (12) month anniversary of the Closing (the “Anniversary Date”), then the Company shall pay to
the Underwriters a cash fee equal to 50% of the Original Fee, or $2,187,500 (the “New Cash Fee”), in
its entirety, within two (2) business days from the Company’s receipt of the Post-Closing Proceeds. For the avoidance of
doubt, the Post-Closing Proceeds shall not include any proceeds received in any financing consummated prior to or simultaneous
with the Closing.

 

     

     

    

 

		3.	If the Merger has consummated and Constellation has failed
to raise the Post-Closing Proceeds by the Anniversary Date, then the Company shall pay to the Underwriters a cash fee equal to
50% of the New Cash Fee, or $1,093,750 (the “50% New Cash Fee”), within one (1) week of the Anniversary
Date. With respect to the remaining balance of $1,093,750 of the New Cash Fee (the “Remaining Balance”),
Cowen may elect to extend the Company’s payment deadline to a future date to be determined at that time, at which point
the Remaining Balance shall be due and payable. If Cowen does not make such an election within two (2) weeks of the Anniversary
Date, then the Company shall, in lieu of the Company paying the Remaining Balance in cash, cause Constellation to issue to the
Underwriters a number of shares of Constellation’s common stock having an aggregate value equal to the Remaining Balance,
assuming a price per share equal to the then Fair Market Value (as defined below) of Constellation’s common stock (the “Alternative
Equity Payment”). “Fair Market Value” shall mean Constellation’s 60-day volume-weighted average
price on the last trading day before Constellation’s issuance of the Alternative Equity Payment, subject to any limitation
imposed by stock exchange rules.

 

		4.	Pursuant to the terms of this Fee Agreement, the Company’s
payment of (i) the New Cash Fee or (ii) the 50% New Cash Fee and the Alternative Equity Payment, in either instance, shall satisfy
the Company’s obligation to pay the Original Fee in full, and no further payment of any kind shall be required of the Company
or Constellation in connection with the Original Fee.

 

		5.	If, during the eighteen (18) month period following the
Closing, the Company proposes to effect any restructuring transaction (through a recapitalization, extraordinary dividend, stock
repurchase, spin-off, joint venture or otherwise), any acquisition or disposition transaction (including, without limitation,
a merger, exchange offer, sale or purchase of assets or capital stock), any bank financing, any public offering, any Rule 144A
offering or any private placement of securities, the Company agrees to offer to engage Cowen as the Company’s exclusive
financial advisor, lead lender or arranger, lead manager underwriter, lead purchaser, or exclusive placement agent, as the case
may be, in connection with such transaction(s) on terms and conditions customary to investment banks for similar transactions;
provided, however, that Cowen may decline in writing such engagement in its sole and absolute discretion at such time. The terms
of such engagements shall be set forth in separate agreements and may be subject to, among other things, satisfactory completion
of due diligence by Cowen, market conditions, the absence of adverse changes to the Company’s business or financial condition,
approval of Cowen’s internal committee and any other conditions that Cowen may deem appropriate for transactions of such
nature.

 

		6.	This Fee Agreement constitutes the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements,
or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter
hereof or the transactions contemplated hereby. This Fee Agreement may not be changed, amended, modified or waived (other than
to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto.

 

    	2

     

    

 

		7.	This Fee Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of New York.

 

		8.	This Fee Agreement may be executed and delivered (including
by facsimile transmission or by electronic transmission) in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one
and the same agreement.

 

[Signature Pages Follow]

 

    	3

     

    

 

	 	CONSTELLATION ALPHA CAPITAL CORP.
	 	 
	 	By: 	/s/ Rajiv Shukla
	 	 	Name:	Rajiv Shukla
	 		Title:	Chief Executive Officer

 

	 	DERMTECH, INC.
	 	 
	 	By:	 /s/ John Dobak
	 	 	Name: John Dobak
	 	 	Title: Chief Executive Officer

 

	Acknowledged and Agreed: 	 

 

	COWEN AND COMPANY, LLC	 
	 	 
	By:	 /s/ Christopher Weekes	 
	 	Name: Christopher Weekes	 
	 	Title: Managing Director	 

 

[Signature Page to Deferred Underwriting
Fee Assignment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]